Printer Friendly

SPI PHARMACEUTICALS INTRODUCES TREATMENT FOR OSTEOPOROSIS IN MEXICO

 COSTA MESA, Calif., Nov. 5 /PRNewswire/ -- SPI Pharmaceuticals, Inc. (AMEX: SPI), announced today the introduction in Mexico of the injectable form of the hormone calcitonin for the treatment of osteoporosis. The prescription pharmaceutical, authorized by the health authorities in Mexico, will be marketed as Oseum(R).
 Daily administration of Oseum retards or halts the loss of calcium from the bones, which can lead to brittleness, and, thus, easy fracture. Osteoporosis is especially prevalent among the growing aging population in Mexico and elsewhere.
 Introduction of calcitonin in Mexico follows its launch in Spain in 1992 by SPI's Spanish subsidiary. Calcitonin sales have expanded in Spain amid favorable medical and patient acceptance.
 "The launch of Oseum signals SPI's continuing drive for growth in Mexico," said Adam Jerney, president and chief operating officer of SPI. "It is also an excellent example of our international capabilities to geographically expand product lines throughout our international manufacturing, marketing and distribution system."
 Mexican operations account for 15 percent of SPI's total revenues. One of the largest pharmaceuticals firms in Mexico, SPI has established a major presence in the anti-infective market. The company's antiviral Virazole is now the largest selling antiviral in the country. In addition, the company makes and markets a broad line of antibiotics.
 As part of the company's long-range expansion plan in Latin America, a full manufacturing modernization program is scheduled for completion in October of next year. It will include installation of state-of-the-art automatic syringe and ampule fillers, electronic ampule inspecting and testing equipment, and a high-speed, fully automated system for filling injectable antibiotics. SPI has 814 employees in Mexico.
 SPI Pharmaceuticals, Inc., headquartered in Costa Mesa, manufactures, markets and distributes more than 600 prescription and non-prescription pharmaceuticals in over 60 countries, including North and Latin America, Western and Eastern Europe, and the Far East. It is an operating unit of ICN Pharmaceuticals, Inc. (NYSE: ICN).
 -0- 11/5/93
 /CONTACT: Jack Sholl, 714-545-0100, ext. 3012/
 (SPI ICN)


CO: SPI Pharmaceuticals, Inc. ST: California IN: MTC SU:

LG-TW -- NY035 -- 1215 11/05/93 11:57 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 5, 1993
Words:342
Previous Article:K-III'S QUANDT TO ASSUME WIDER ROLE IN DIRECT RESPONSE
Next Article:NEW YORK SELECTS ENVIROTEST FOR LARGEST AUTO EMISSIONS TESTING CONTRACT TO DATE IN THE INDUSTRY
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters